-transparent.png){kind=logo}
Migration inhibition factor (MIF) activity, expressed as a migration index, was studied in the sera of 48 chronic lymphatic leukemia (CLL) patients and 48 healthy controls. MIF activity was detected in the sera of 50% of the CLL patients. The medical condition of patients in advanced clinical stages (III and IV) and with detectable MIF activity was more stable (after 18-mo follow-up) than was that of the patients in advanced stages but without detectable MIF activity. No relationship was found between the clinical stage of the disease, absolute lymphocyte count, and MIF activity.
Related Publications
D Benjamin, and
D Aderka, and
E Livni, and
H Joshua, and
M Shaklai, and
J Pinkhas
January 1984,
Archiv fur Geschwulstforschung,
D Benjamin, and
D Aderka, and
E Livni, and
H Joshua, and
M Shaklai, and
J Pinkhas
October 1971,
Przeglad lekarski,
D Benjamin, and
D Aderka, and
E Livni, and
H Joshua, and
M Shaklai, and
J Pinkhas
June 1974,
Clinica chimica acta; international journal of clinical chemistry,
D Benjamin, and
D Aderka, and
E Livni, and
H Joshua, and
M Shaklai, and
J Pinkhas
December 1996,
American journal of hematology,
D Benjamin, and
D Aderka, and
E Livni, and
H Joshua, and
M Shaklai, and
J Pinkhas
September 1976,
International journal of cancer,
D Benjamin, and
D Aderka, and
E Livni, and
H Joshua, and
M Shaklai, and
J Pinkhas
January 1977,
Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
D Benjamin, and
D Aderka, and
E Livni, and
H Joshua, and
M Shaklai, and
J Pinkhas
January 1994,
Advances in experimental medicine and biology,
D Benjamin, and
D Aderka, and
E Livni, and
H Joshua, and
M Shaklai, and
J Pinkhas
June 1979,
Clinical and experimental immunology,
D Benjamin, and
D Aderka, and
E Livni, and
H Joshua, and
M Shaklai, and
J Pinkhas
May 1960,
Nordisk medicin,
D Benjamin, and
D Aderka, and
E Livni, and
H Joshua, and
M Shaklai, and
J Pinkhas
January 1974,
Tissue antigens,
